T1	Participants 83 112	foscarnet maintenance therapy
T2	Participants 630 638	Patients
T3	Participants 1545 1589	Patients receiving higher doses of foscarnet
T4	Participants 1832 1872	atients with cytomegalovirus retinopathy
